Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/AstraZeneca shares drop nearly 9% after heart drug trial fails main goal

AZN

$161.91

+$0.49 +0.30%

AstraZeneca shares drop nearly 9% after heart drug trial fails main goal

Market News

09 Jul 2026

CNBC

View Source

Bearish

AstraZeneca's shares fell nearly 9% after its experimental heart drug, Wainua, failed to meet the primary goal in a late-stage trial. The drug aimed to reduce deaths and heart-related emergencies over 140 weeks for patients with a rare heart condition called transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The failure marks a significant setback for the British drugmaker, with shares hitting their worst day since March 2020. Investors will be watching closely for AstraZeneca's next steps following this trial result.

More News (AZN)

New report analyzes 1,350+ precision medicine deals from 2019-2026, revealing market trends and deal structures.

ResearchAndMarkets.com released a comprehensive report covering over 1,350 precision medicine collaboration and licensing deals from 2019 to 2026. The report offers detailed insights into deal structures, financial terms, and partnership strategies, ...

Others

Neutral

3 days ago